Hybrid necroptosis inhibitors
US-2016024098-A1 · Jan 28, 2016 · US
Heterocyclic amides as kinase inhibitors
US9556152B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9556152-B2 |
| Application number | US-201414763183-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 14, 2014 |
| Priority date | Feb 15, 2013 |
| Publication date | Jan 31, 2017 |
| Grant date | Jan 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds having the formula: wherein X, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 5 , R A , m, A, L, and B are as defined herein, and methods of making and using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is: or a tautomer thereof, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 and one or more pharmaceutically acceptable excipients. 3. A method of treating ulcerative colitis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 4. A method of treating Crohn's disease comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 5. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 6. A method of treating psoriasis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 7. A method of treating spondyloarthritis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 8. A method of treating SoJIA comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 9. A method of treating osteoarthritis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 10. A method of treating multiple sclerosis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof. 11. A compound which is: or a tautomer thereof. 12. A pharmaceutical composition comprising the compound, or a tautomer thereof, according to claim 11 and one or more pharmaceutically acceptable excipients. 13. A method of treating ulcerative colitis comprising administering a therapeutically effective amount of the compound according to claim 11 to a human in need thereof. 14. A method of treating Crohn's disease comprising administering a therapeutically effective amount of the compound, or tautomer thereof, according to claim 11 to a human in need thereof. 15. A method of treating rheumatoid arthritis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, according to claim 11 to a human in need thereof. 16. A method of treating psoriasis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, according to claim 11 to a human in need thereof. 17. A method of treating spondyloarthritis comprising administering a therapeutically effective amount of the compound according to claim 11 to a human in need thereof. 18. A method of treating SoJIA comprising administering a therapeutically effective amount of the compound according to claim 11 to a human in need thereof. 19. A method of treating osteoarthritis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, according to claim 11 to a human in need thereof. 20. A method of treating multiple sclerosis comprising administering a therapeutically effective amount of the compound, or tautomer thereof, according to claim 11 to a human in need thereof.
Assignees
Inventors
Classifications
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9556152B2 cover?
- Disclosed are compounds having the formula: wherein X, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 5 , R A , m, A, L, and B are as defined herein, and methods of making and using the same.
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/55. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).